Dermatitis

LATEST NEWS

Atopic Dermatitis Incidence May Be Lower in Infants With Early-Life Farm Exposure

By

Emily Pond

Pre- and early postnatal farm exposure was found to be associated with reduced incidence of atopic dermatitis in infants.

Dry Eye Disease, Food Allergies Linked to Dupilumab-Induced Ocular AEs in Patients With AD

By

Brandon May

Therapy-induced ocular adverse events may be associated with pre-existing dry eye disease, eyelid eczema, and a history of a food allergy, among other conditions.

Dupilumab for AD May Reduce Work, School Absenteeism

By

Brandon May

Dupilumab displayed significant reductions in work and school absenteeism with associated cost savings.

S. aureus Agr Virulence Tied to Atopic Dermatitis in Infants

Skin colonization by Staphylococcus aureus is associated with the risk for developing AD, and infants who do not develop AD primarily exhibit acquisition of dysfunctional mutations in the S. aureus quorum-sensing system.

Asthma, Atopic Dermatitis Associated With Poor Sleep Outcomes in Urban Children

By

Brandon May

Children with asthma and atopic dermatitis who live in urban areas may be at a higher risk for poor sleep outcomes.

Nemolizumab Beats Placebo for Reduction of Pruritus in Eczema

For patients with atopic dermatitis and moderate-to-severe pruritus, nemolizumab results in a greater reduction in pruritus than placebo.

Itching in Severe Atopic Dermatitis Linked to Dry Skin, Dust Mites, and Emotional Distress

By

Emily Pond

Skin dryness, dust exposure, and distress play an essential role in the exacerbation of atopic dermatitis in the adult population.

Second Trial Evaluating Upadacitinib in Atopic Dermatitis Meets End Point

By

Brian Park, PharmD

Positive results from the second phase 3 study of upadacitinib (Rinvoq; AbbVie) showed that it met all primary and secondary end points for the treatment of moderate to severe atopic dermatitis.

FDA to Review Tralokinumab for Moderate to Severe Atopic Dermatitis

By

Brian Park, PharmD

The FDA has accepted for review the Biologics License Application (BLA) for tralokinumab.

Dupilumab Reduces Atopic Dermatitis Flares

By

Brandon May

Dupilumab provides long-term control of AD and prevents disease flares, which may help reduce the need for escalation and/or intensification of therapy.